Research Article

Management and Microbiological Characteristics of Membrane Formation on a Hydrophilic Acrylic Intraocular Lens: A Clinical Case Series and Material Comparative Study of Different IOLs

Table 1

The demographics of the ten cases implanted with QUATRIX Aspheric IOLs.

Case no.AgeGenderMedical historyOphthalmic historyPreoperative VAOnset (days)VA on POEAnterior chamberVitreous opacificationAC/vitreous tappingTropical treatmentSystemic treatmentFinal VAFinal BCVA

174MAMD20/1003220/200Tyn (+) Cell (+)MildNoLevofloxacin and tobramycin eye dropOral levofloxacin20/5020/25
270FHypertension20/2005520/400Tyn (++) Cell (++)Mild to moderateYes, (-)Intravitreal ceftazidime + norvancomycinIntravenous levofloxacin20/8020/40
364M20/80520/200Tyn (+) Cell (+)MildNoGatifloxacin and tobramycin eye dropIntravenous levofloxacin20/4020/25
474F20/100920/100Tyn (+) Cell (+)MildNoGatifloxacin and tobramycin eye dropOral levofloxacin20/4020/32
576FHypertension20/2002620/200Tyn (++) Cell (++)Mild to moderateYes, (-)Intravitreal ceftazidime + norvancomycinIntravenous levofloxacin20/8020/50
658FDiabetes20/2004020/400Tyn (+++) Cell (++++)Mild to moderateYes, (-)YAG + PPV + Intravitreal ceftazidime + norvancomycinOral levofloxacin20/4020/25
767F20/100320/200Tyn (+) Cell (+)Mild to moderateNoGatifloxacin and tobramycin eye dropOral levofloxacin20/5020/32
856MPathological myopia20/4006520/2000Tyn (+++) Cell (++)ModerateYes, S. epiPPV + Intravitreal ceftazidime + norvancomycinOral levofloxacin20/10020/40
974F20/802420/200Tyn (+) Cell (+)Mild to moderateNoGatifloxacin eye drop + YAGOral levofloxacin20/2020/25
1052MPathological myopia20/501620/400Tyn (++) Cell (++)Mild to moderateYes, (-)Intravitreal ceftazidime + norvancomycinOral cefaclor20/5020/32

AMD = age-related macular degeneration; VA = visual acuity; BCVA = best-corrected visual acuity; PPV = pars plana vitrectomy; YAG = yttrium aluminium garnet.